David Gearing
Plus aucun poste en cours
Profil
David Gearing was the founder of Millennium Biotherapeutics, Inc. (founded in 1996) and Nexvet Australia Pty Ltd.
(founded in 2010, where he held the title of Chief Scientific Officer).
He held former positions as Director-Molecular Biology at Systemix, Inc. (1994-1995), Staff Scientist at Immunex Corp.
(1990-1994), Chief Research Officer & Research Director at CSL Ltd.
(2000-2007), Entrepreneurs-in-Residence at The University of Queensland, and Professor at Monash Institute of Medical Research.
Dr. Gearing received his undergraduate degree from the University of Leeds and his doctorate from Monash University.
Dr. Gearing is also the founder of Nexvet Biopharma Plc.
Anciens postes connus de David Gearing
| Sociétés | Poste | Fin |
|---|---|---|
| NEXVET BIOPHARMA PUBLIC LIMITED CO | Fondateur | 10/03/2017 |
| CSL LIMITED | Directeur Technique/Scientifique/R&D | - |
| Millennium Biotherapeutics, Inc. | Fondateur | - |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Corporate Officer/Principal | - |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Directeur Technique/Scientifique/R&D | - |
Formation de David Gearing
| University of Leeds | Undergraduate Degree |
| Monash University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CSL LIMITED | Health Technology |
| Entreprise privées | 6 |
|---|---|
Nexvet Australia Pty Ltd.
 Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
| Millennium Biotherapeutics, Inc. | |
Nexvet Biopharma Plc
 Nexvet Biopharma Plc Pharmaceuticals: MajorHealth Technology Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland. | Health Technology |
| Monash Institute of Medical Research |